Related Experiment Video
Updated: Jul 14, 2026
Endobronchial Ultrasound-guided Intratumoral Injection of Cisplatin for the Treatment of Isolated Mediastinal Recurrence of Lung Cancer
Published on: February 12, 2017
[Phase I study of docetaxel combined with carboplatin in patients with non-small cell lung cancer]
Li-Ming Zhu1, Qiu-Yun Li, Xin-Min Yu
1Department of Chemotherapy Center, Zhejiang Province Cancer Hospital, Hangzhou 310022, China. hzhzazlm@hotmail.com
Objective:
To determine the maximum tolerated dose (MTU) and dose-limiting toxicity (DLT) of Docetaxel and Carboplatin in patients with non-small cell lung cancer.
Methods:
Docetaxel was given at escalating doses until MTD was determined from the initial dose of 65 mg/m2 to 75 mg/m2, 85 mg/ m2 on dl. Carboplatin was targeted to an area under the plasma concentration curve of 5 using Calver's equation on dl. The treatment cycle was repeated every 3 weeks.
Results:
16 patients received TXT and CBP for total of 54 courses (median four courses). Neutropenia was the dose-limiting toxicity. The MTD of TXT is 85 mg/m2.
Conclusion:
We recommend TXT 75 mg/m2 on d1 and CBP with a target AUC of 5 on d1, 3weeks repeated for chemotherapy in naïve patients with NSCLC.